Celltrion Reveals Data As It Rolls Out Higher-Strength Adalimumab
Presents One-Year Data From Phase III Trial For Yuflyma Rival To Humira
As it begins to roll out its Yuflyma higher-strength adalimumab biosimilar in Europe, Celltrion has reported positive one-year data from a Phase III trial for the 100mg/ml Humira rival.
